Biomarkers in Cancer Detection, Diagnosis, and Prognosis.
Sreyashi DasMohan Kumar DeyRam DevireddyManas Ranjan GartiaPublished in: Sensors (Basel, Switzerland) (2023)
Biomarkers are vital in healthcare as they provide valuable insights into disease diagnosis, prognosis, treatment response, and personalized medicine. They serve as objective indicators, enabling early detection and intervention, leading to improved patient outcomes and reduced costs. Biomarkers also guide treatment decisions by predicting disease outcomes and facilitating individualized treatment plans. They play a role in monitoring disease progression, adjusting treatments, and detecting early signs of recurrence. Furthermore, biomarkers enhance drug development and clinical trials by identifying suitable patients and accelerating the approval process. In this review paper, we described a variety of biomarkers applicable for cancer detection and diagnosis, such as imaging-based diagnosis (CT, SPECT, MRI, and PET), blood-based biomarkers (proteins, genes, mRNA, and peptides), cell imaging-based diagnosis (needle biopsy and CTC), tissue imaging-based diagnosis (IHC), and genetic-based biomarkers (RNAseq, scRNAseq, and spatial transcriptomics).
Keyphrases
- healthcare
- clinical trial
- high resolution
- randomized controlled trial
- magnetic resonance imaging
- computed tomography
- single cell
- end stage renal disease
- stem cells
- gene expression
- chronic kidney disease
- contrast enhanced
- genome wide
- type diabetes
- bone marrow
- squamous cell
- pet ct
- adipose tissue
- mesenchymal stem cells
- metabolic syndrome
- skeletal muscle
- social media
- cell therapy
- phase ii
- loop mediated isothermal amplification
- label free
- circulating tumor cells
- childhood cancer
- study protocol
- dna methylation
- open label
- circulating tumor
- weight loss